Drugs / AMX0035
Trials 5
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 22 trials · 1 met primary | ||||||
| Phase 2 | NCT05676034 | Mar 2023 → Jul 2024 overdue | Wolfram syndrome | Amylyx Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase 2 | NCT03127514 | Jun 2017 → Sep 2019 | TDP-43 proteinopathy, amyotrophic lateral sclerosis | Amylyx Pharmaceuticals Inc. | Completed | Met primary |
| Phase 2/31 trial | ||||||
| Phase 2/3 | NCT06122662 | Dec 2023 → Sep 2025 | parkinsonian disorder, progressive supranuclear palsy | Amylyx Pharmaceuticals Inc. | Completed | No outcome recorded |
| Phase 31 trial | ||||||
| Phase 3 | NCT05021536 | Oct 2021 → Jan 2024 overdue | amyotrophic lateral sclerosis | Amylyx Pharmaceuticals Inc. | Active not recruiting | No outcome recorded |
| Phase not stated1 trial | ||||||
| — | NCT05286372 | — | amyotrophic lateral sclerosis | Amylyx Pharmaceuticals Inc. | Approved for marketing | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 5 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | AMX0035 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03127514 ↗ |
| Route | Oral | “AMX0035 administered by mouth or via feeding tube for 24 weeks” NCT03127514 ↗ |